Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2025 06:00 ET | Source: BlueRock Therapeutics

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel

Cambridge, MA USA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned independeltly operated subsidiary of Bayer AG, today announced...
April 16, 2025 11:15 ET | Source: BlueRock Therapeutics

BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease

Cambridge, MA USA, April 16, 2025 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced the publication of the...
September 03, 2024 07:30 ET | Source: BlueRock Therapeutics

BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases

Cambridge, MA USA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced...
May 30, 2024 02:30 ET | Source: BlueRock Therapeutics

BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel

Berlin, Germany and Cambridge, MA, USA, May 30, 2024 (GLOBE NEWSWIRE) -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated...
March 25, 2024 07:30 ET | Source: BlueRock Therapeutics

BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases

CAMBRIDGE, MA USA and COLUMBIA, MD, March 25, 2024 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer...
March 06, 2024 02:30 ET | Source: BlueRock Therapeutics

BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months

Berlin, Germany and Cambridge, MA USA,, March 06, 2024 (GLOBE NEWSWIRE) -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated...